Immunic (NASDAQ:IMUX) announced Tuesday that an independent panel has recommended that the company continue its Phase 3 ...

On Friday, Immunic Inc (IMUX) stock saw a decline, ending the day at $1.19 which represents a decrease of $-0.02 or -1.65% from the prior close of $1.21. The stock opened at $1.21 and touched a low of ...

Shares of Immunic rose after the biopharmaceutical company reported a positive outcome in its interim analysis of a treatment for relapsing multiple sclerosis. The New York-based company's stock price ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Leerink Partners has recently resumed Immunic Inc (IMUX) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on August 27, 2024, B. Riley Securities had ...

NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline ...

Tuesday announced positive outcome from the interim futility analysis of its Phase 3 ENSURE program evaluating ...

A pair of Phase 3 trials testing vidofludimus calcium in relapsing MS are continuing as planned after a positive committee ...

Immunic (IMUX) announced the outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program, investigating lead asset, nuclear receptor related 1, or Nurr1, activator ...

Immunic (NASDAQ:IMUX) announced Tuesday that an independent panel has recommended that the company continue its Phase 3 ENSURE program for its lead asset vidofludimus calcium (IMU-838) without any ...

Immunic to Participate in Industry, Scientific and Investor Conferences in November 29.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to ...